THERAPY DOSSIER · th-40950eb41c4e

Anti-interferon-gamma monoclonal antibody R46-A2

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32763819 ↗2020Reported benefit

Temporary blockade of interferon-gamma ameliorates doxorubicin-induced cardiotoxicity without influencing the anti-tumor effect.

MouseChemical/toxinBALB/c and C57BL/6FemaleGiven simultaneously with repeated doxorubicin dosing, or as a single late inje…

Model: Doxorubicin-induced chronic cardiotoxicity in tumour-bearing and tumour-free mice

Simultaneous or late anti-interferon-gamma antibody treatment preserved cardiac function after doxorubicin without impairing tumour suppression or the main cellular immune response.

Extraction: extract · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.

Loading the evidence…